Oxaliplatin side effects linked to HMGB1 blood levels
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study checks if a substance called HMGB1 in your blood is linked to nerve damage and liver side effects from the chemotherapy drug oxaliplatin. It is for people with a specific type of stomach or pancreas cancer that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma of the esophagus, stomach, or pancreas, and the tumor can be removed with surgery.
- You are in good general health, able to do light work or fully active (ECOG 0 or 1).
- You have not been treated with oxaliplatin before.
- You are scheduled to receive a specific chemotherapy regimen (FLOT, FOLFOX, or FOLFIRINOX) before and after surgery.
- You do not have severe organ problems (like liver, kidney, heart failure) or take blood thinners.
- You are able to speak and understand French, and are registered in the French healthcare system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This early-phase study tests how safe and workable it is to combine irinotecan with several standard chemotherapy medicines for cancers like pancreatic and other upper GI cancers. It’s mainly looking for side effects and the best way the doses work in people with advanced or metastatic disease.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This study looks at how your genes affect the way your body handles the chemotherapy drug capecitabine when it's taken with oxaliplatin. The goal is to understand if certain genetic differences can impact drug levels, which may help personalize treatment in the future.
This trial tests a drug called AC591 to see if it can prevent nerve damage (tingling, numbness, pain) caused by oxaliplatin, a common chemo drug for colorectal cancer. It is for people starting CAPEOX chemo after colon cancer surgery.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.